

Electronic Acknowledgement Receipt

EFS ID:	3379849
Application Number:	10584151
International Application Number:	
Confirmation Number:	7001
Title of Invention:	Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
First Named Inventor/Applicant Name:	Gerard Molnet
Customer Number:	23599
Filer:	Csaba Henter/Pamela Richardson
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	MERCK-3186
Receipt Date:	30-MAY-2008
Filing Date:	22-JUN-2006
Time Stamp:	12:49:34
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	8469
Deposit Account	
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	----------------------------------	------------------	------------------

1		Reply-5-30-08.pdf	222705 3c108719b795514b88889061a73ad4f561b3d8a	yes	6
	Multipart Description/PDF files in .zip description				
	Document Description	Start	End		
	Amendment - After Non-Final Rejection	1	1		
	Claims	2	5		
	Applicant Arguments/Remarks Made in an Amendment	6	6		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed	InformationDisclosureStatement-5-30-08.pdf	168383 c062c4993aacd474a8f8efc120745a127e9767b08a	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Filed	PTO-1449-5-30-08.pdf	201589 636c0296c27703761b14eebc3f333995c57db25	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	WO03010146.pdf	13246262 8aed5baa32b087711245642b2db41e2574480d0	no	283
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	EP0433679A3.pdf	87786 26c0b4c4605233246132533dc9a7610ba465c2793	no	3
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
6	Foreign Reference	EP0398283B1.pdf	3258106 8399b9bde4e021a5c1d9d96790cc0e141233b28f50a6	no	75
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
7	Foreign Reference	FR2791263.pdf	428469 8baa8498906e775237d1821647b75fb505d4c03e79	no	9

Warnings:					
Information:					
8	Foreign Reference	WO2004007461.pdf	6619326 ada79c1f112886f72ad102591380e670642d75c94d	no	149
Warnings:					
Information:					
9	Foreign Reference	WO2004045614.pdf	2079643 8df7ae4dca693d5276cd93a5e183872b1689e3a3	no	41
Warnings:					
Information:					
10	NPL Documents	HarrisonBoydEtAl-4-Carboxymethoxy-XP001199578.pdf	334074 a00073f77ca2b00548b087b7b6e287ba4965fcdff	no	3
Warnings:					
Information:					
11	NPL Documents	SalituroEtAl-3-2-Carboxyindole-3-yl-Propionic.pdf	1192071 65d09e665131b43cc2c62a97c29292033e652bd14	no	9
Warnings:					
Information:					
12	NPL Documents	KotakeEtAl-XP-002294269-XanthurenicAcidXVI.pdf	48287 230931ce46f93bd4765ea33f524aa0030c03ae9262	no	1
Warnings:					
Information:					
13	NPL Documents	CarvalhoEtAl-RoleOfEndogenousAngiotensin.pdf	690199 ba54961c620a0b7ba56213f5bd2c1c1da3e56a851	no	6
Warnings:					
Information:					
14	NPL Documents	KotakeEtAl-APossibleDiabetogenicRoleForTryptophan.pdf	323631 cb6b983406441f5234c0348593854af2336a2b61	no	4
Warnings:					
Information:					
15	NPL Documents	SandersEtAl-L-AminoAcidInhibitionOfEpinephrine.pdf	575792 9cd31238529bce4e009a4c84d958a7c98748933d7f	no	10
Warnings:					
Information:					
16	NPL Documents	StoneEtAl-EndogenousKynureninesAsTargets.pdf	1529544 b30ff1bf62d4066b6578677a54ac5a5a6a932c4c26	no	12

Warnings:					
Information:					
17	NPL Documents	EdmontEtAl-SynthesisAndEvaluationOfQuinoline.pdf	262548 <small>41abaf6ec30b639fafc04b55ec3231aebbd46778d7</small>	no	4
Warnings:					
Information:					
18	NPL Documents	Nicolaus-SymbioticApproachToDrugDesign.pdf	827554 <small>3710ebf33a071ef4a4553b1ba0552d019874d5edf</small>	no	14
Warnings:					
Information:					
19	Fee Worksheet (PTO-06)	fee-info.pdf	8250 <small>f0595e50007093324bea8b9e9700194e105c06c37</small>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			32104219		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					